Scaling NK Cell manufacturing: From iPSCs to NK cells in a feeder-free, GMP-ready platform

Published on April 16, 2025
Scaling NK Cell manufacturing: From iPSCs to NK cells in a feeder-free, GMP-ready platform

Natural Killer (NK) cell treatments are not readily accessible to patients due to persistent manufacturing complexities, scalability issues, and challenges in delivery. Cellistic's iPSC-based allogeneic Echo™-NK Manufacturing Platform breaks down these barriers by enabling therapeutic developers to manufacture safe, consistent, and cost-efficient off-the-shelf NK cell therapies at scale.

Continue reading on website
Other news

Webinar: Mastering challenges in iPSC-derived allogeneic cell drug product manufacturing

April 14, 2025

The resurgence of mental health drug development and why it matters

April 16, 2025
After decades of stagnation, the field of mental health drug development is finally seeing some movement. A wave of innovation, bolstered by new science, shifting public attitudes, and landmark regulatory moments, is transforming how we understand and treat mental health conditions. “It’s like we’ve been playing the same song on repeat,” says Emma Wille, a […]